Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A STUDY OF ELRANATAMAB MANAGEMENT WITH OUTPATIENT AND INTERMITTENT DOSING IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EMBRACE TRIAL

Intervention/treatment:
ELREXFIO / ACTEMRA (TOZILIZUMAB) / DEXAMETHASONE
Medical condition:
RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Protocol code:
OCOG-2023-EMBRACE
Control number:
285336
Status:
Recruiting
Approved:
May 13, 2024
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT06421675
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Emilio Aguirre, CRA,HIT,CHIM
Role
CONTACT
Phone:
905-527-2299
Extension 42650
Name
Daryl Solomon
Role
CONTACT
Phone:
905-527-2299
Extension 42622
Sponsor
MCMASTER UNIVERSITY

Locations

British Columbia

Vancouver Cancer Center
Vancouver, British Columbia, V5Z 1L3
RECRUITING
Name
Christopher Venner, MD
Role
CONTACT
Phone:
604-877-6000

Ontario

Juravinski Cancer Center
Hamilton, Ontario, L8V 1C3
RECRUITING
Name
Hira Mian, MD
Role
CONTACT
Phone:
905-387-9495
Kingston General Hospital
Kingston, Ontario, K7L 2V7
RECRUITING
Name
Ashlee Young, Trial Activation Coordinator
Role
CONTACT
Phone:
613-549-6666
Name
Bethany Monteith, MD
Role
PRINCIPAL_INVESTIGATOR
London Health Science Centre - Victoria Hospital
London, Ontario, N6A 5W9
RECRUITING
Name
Arleigh Robertson McCurdy, MD
Role
CONTACT
Phone:
613-737-8899
Extension 71281
London Health Science Centre - Victoria Hospital
London, Ontario, N6A 5W9
RECRUITING
Name
Martha de Lacerda Louzada, MD
Role
CONTACT
Phone:
613-737-8899
Extension 519-685-8500
Ottawa Hospital
Ottawa, Ontario, K1H 8L6
RECRUITING
Name
Arleigh Robertson McCurdy, MD
Role
CONTACT
Phone:
613-737-8899
Extension 71281
Did you find what you were looking for?

Contacts and resources